Packaging systems for human recombinant adenovirus to be used in gene therapy

• US 6,306,652 B1
• Filed: 06/15/1999
• Issued: 10/23/2001
• Est. Priority Date: 06/15/1995
• Status: Expired due to Term

• Current Assignee: Crucell Holland B.V (Johnson & Johnson)
• Original Assignee: Introgene BV (Johnson & Johnson), Rijksuniversiteit
• Inventors: Bout, Abraham, Valerio, Domenico, Hoeben, Robert Cornelis, Fallaux, Frits Jacobus, Van Der Eb, Alex Jan
• Primary Examiner(s): Priebe, Scott D.
• Assistant Examiner(s): Nguyen, Dave Trong
• Application Number:
  US09/333,820
• Time in Patent Office: 861 Days
• Field of Search: 435/69.1, 435/320.1, 435/325, 435/455, 424/93.21
• US Class Current: 435/325
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C12N 15/86 Viral vectors
• CPC Class Codes: C12N 2710/10321 Viruses as such, e.g. new isolates, mutants or their genomic sequences
• CPC Class Codes: C12N 2710/10343 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2710/10351 Methods of production or purification of viral material
• CPC Class Codes: C12N 2710/10352 relating to complementing cells and packaging systems for producing virus or viral particles
• CPC Class Codes: C12N 2830/00 Vector systems having a special element relevant for transcription
• CPC Class Codes: C12N 2830/15 chimeric enhancer/promoter combination
• CPC Class Codes: C12N 2830/42 being an intron or intervening sequence for splicing and/or stability of RNA
• CPC Class Codes: C12N 2830/60 from viruses
• CPC Class Codes: C12N 7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00

Abstract

Presented are ways to address the problem of replication competent adenovirus in adenoviral production for use with, for example, gene therapy. Packaging cells having no overlapping sequences with a selected vector and are suited for large scale production of recombinant adenoviruses. A method of the invention produces adenovirus incapable of replicating. The method includes a primary cell containing a nucleic acid based on or derived from adenovirus and an isolated recombinant nucleic acid molecule for transfer into the primary cell. The isolated recombinant nucleic acid molecule is based on or derived from an adenovirus, and further has at least one functional encapsidating signal, and at least one functional Inverted Terminal Repeat. The isolated recombinant nucleic acid molecule lacks overlapping sequences with the nucleic acid of the cell. Otherwise, the overlapping sequences would enable homologous recombination leading to replication competent adenovirus in the primary cell into which the isolated recombinant nucleic acid molecule is to be transferred.

Claims

1. A method for producing a replication defective adenovirus comprising a gene of interest, without the concomitant production of replication competent adenovirus through homologous recombination, said method comprising:

a) providing a cell, said cell harboring a first adenoviral nucleic acid encoding adenoviral E1A and E1B gene products, and wherein said first adenoviral nucleic acid further comprises a deletion starting directley after a nucleotide after the furthest downstream E1B stop codon;

b) transferring a recombinant nucleic acid into said cell, said recombinant nucleic acid comprising;

a second adenoviral nucleic acid, and

comprising at least one functional encapsidating signal, and at least two functional Inverted Terminal Repeats, said recombinant nucleic acid lacking overlapping sequences with the first adenoviral nucleic acid leading to replication competent adenovirus;

c) culturing said cell; and

d) harvesting replication defective adenovirus produced from said cell.

2. The method according to claim 1 wherein said recombinant nucleic acid is in linear form and comprises functional Inverted Terminal Repeats at or near both termini.

3. The method according to claim 1 wherein said cell is a primary cell.

4. The method of claim 1 wherein said recombinant nucleic acid is DNA.

5. The method of claim 2 wherein said recombinant nucleic acid is DNA.

6. The method of claim 3 wherein said recombinant nucleic acid is DNA.

7. The method according to claim 1 wherein said cell is a primary cell, which harbors, in its genome, sequences encoding E1A and E2A gene products and wherein the sequences encoding the E2A region gene product is selected from the group consisting of a DNA sequence encoding the wild-type E2A region operably linked to an inducible promoter and a DNA sequence encoding a temperature sensitive 125 mutation.

8. A method according to claim 7 wherein said E2A region is under the control of an inducible promoter.

9. A method according to claim 7 wherein said E2A region is mutated so that at least one of its products is temperature sensitive.

10. A method according to claim 8 wherein said E2A region is mutated so that at least one of its products is temperature sensitive.

11. The method according to claim 7 wherein said producer cell is a diploid cell.

12. The method according to claim 8 wherein said producer cell is a diploid cell.

13. The method according to claim 7 wherein said producer cell is of non-human origin.

14. The method according to claim 8 wherein said producer cell is of non-human origin.